News

Mucinex Allergy joins lineup

BY Michael Johnsen

Reckitt Benckiser recently extended its Mucinex brand into the allergy set with the appropriately named Mucinex Allergy. “Super fantastic launch in the United States,” said Heather Allen, Reckitt Benckiser EVP category development, recently to investors. “Allergy is a $2.5 billion market in the United States. More than 75% of Mucinex users also take an allergy treatment, and now, we’re able to offer them Mucinex Allergy, a maximum strength, non-drowsy antihistamine [that] acts fast and lasts for 24 hours.”

(For the complete category review, including data, click here.)

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Chattem redefines ‘shelf talker’

BY Michael Johnsen

With the recent switch of Chattem’s Nasacort 24HR, the first nasal corticosteroid to be sold OTC, Chattem launched a very unique marketing tool — an interactive shelf display that gives a whole new meaning to the term “shelf talker.” With the press of a button, shoppers could watch a short video on how Nasacort 24HR worked and why they should consider the new nasal product to be their allergy remedy of choice.

(For the full category review, including data, click here.)

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Longer season spurs additional remedies

BY Michael Johnsen

The allergy remedy business is growing, and not just because of new entries to the market like Chattem’s Nasacort 24HR, which to date has brought in more than $50 million to the category. Allergy seasons are lasting longer, and there are more people suffering from allergies.

(For the complete category review, including data, click here.)

Allergies represent the fifth most-common chronic disease in the United States, impacting 1-in-5 Americans. And as many as 90% of allergy sufferers self-treat their condition, while 40% of allergy sufferers report moderate to severe symptoms and 38% report those symptoms are intolerable.

Approximately 40 million Americans have indoor-outdoor allergies. Approximately 10 million people are allergic to cat dander, the most common pet allergy. The most common indoor-outdoor allergy triggers are tree, grass and weed pollen; mold spores; dust mite and cockroach allergen; and cat, dog and rodent dander.

Approximately 4% of allergy sufferers have eye allergies as their primary allergy, often caused by many of the same triggers as indoor-outdoor allergies.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?